183 related articles for article (PubMed ID: 20489159)
1. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.
Ogawa T; Fujii H; Yoshizato K; Kawada N
Am J Pathol; 2010 Jul; 177(1):153-65. PubMed ID: 20489159
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
3. Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
Horn CL; Morales AL; Savard C; Farrell GC; Ioannou GN
Hepatol Commun; 2022 Jan; 6(1):12-35. PubMed ID: 34558856
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model.
Oishi T; Terai S; Kuwashiro S; Fujisawa K; Matsumoto T; Nishina H; Sakaida I
Biochem Biophys Res Commun; 2012 May; 422(1):22-7. PubMed ID: 22554516
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
6. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Zou Y; Li J; Lu C; Wang J; Ge J; Huang Y; Zhang L; Wang Y
Life Sci; 2006 Aug; 79(11):1100-7. PubMed ID: 16624332
[TBL] [Abstract][Full Text] [Related]
7. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.
Velayudham A; Dolganiuc A; Ellis M; Petrasek J; Kodys K; Mandrekar P; Szabo G
Hepatology; 2009 Mar; 49(3):989-97. PubMed ID: 19115316
[TBL] [Abstract][Full Text] [Related]
8. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
9. [Rabbit model for the study of human NASH].
Otogawa K; Kawada N
Nihon Rinsho; 2006 Jun; 64(6):1043-7. PubMed ID: 16768107
[TBL] [Abstract][Full Text] [Related]
10. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
11. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
Enjoji M; Nakamuta M
World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of c-Jun in nonalcoholic fatty liver disease.
Dorn C; Engelmann JC; Saugspier M; Koch A; Hartmann A; Müller M; Spang R; Bosserhoff A; Hellerbrand C
Lab Invest; 2014 Apr; 94(4):394-408. PubMed ID: 24492282
[TBL] [Abstract][Full Text] [Related]
13. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.
Mells JE; Fu PP; Kumar P; Smith T; Karpen SJ; Anania FA
J Nutr Biochem; 2015 Mar; 26(3):285-92. PubMed ID: 25577467
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
15. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
[TBL] [Abstract][Full Text] [Related]
16. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats.
Xu ZJ; Fan JG; Ding XD; Qiao L; Wang GL
Dig Dis Sci; 2010 Apr; 55(4):931-40. PubMed ID: 19459046
[TBL] [Abstract][Full Text] [Related]
17. Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha.
Ramirez-Tortosa MC; Ramirez-Tortosa CL; Mesa MD; Granados S; Gil A; Quiles JL
Free Radic Biol Med; 2009 Oct; 47(7):924-31. PubMed ID: 19539747
[TBL] [Abstract][Full Text] [Related]
18. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
20. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
Sugino H; Kumagai N; Watanabe S; Toda K; Takeuchi O; Tsunematsu S; Morinaga S; Tsuchimoto K
J Gastroenterol Hepatol; 2008 Dec; 23(12):1909-16. PubMed ID: 18422963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
